• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    New antibacterial agents are compounds of formula …<CHEM>… wherein R is hydrogen atom or C1-C4 alkyl group optionally substituted from halogen atom or hydroxy group optionally protected, A is Z, ZOCO or ZCO residue, wherein Z is phenylene, naphthylene, heterocyclediyl, C1-C7 alkylene, C2-C4 alkenylene, alkynylene, …<CHEM>…, C3-C8 cycloalkylene, aralkylene radical optionally substituted, and Q<(+)> represents a group …<CHEM>…, wherein R1, R2 and R3 are each either: … … (i) optionally substituted alkyl, aralkyl or aryl radical or … (ii) R1 is as defined above under (i) and R2, R3, taken together, represent an optionally substituted or fused heterocyclic radical or … (iii) R1, R2, R3 taken together, represent an optionally substituted azonia-bicyclo or tricyclo radical or … (iv) R1, R2, R3, taken together, represent an optionally substituted or fused pyridinium, pyrazinium, pyrazolium or pyridazinium radical, and the pharmaceutically or veterinarily acceptable salts thereof. … …<??>The compounds are prepared by reacting the amine NR, R<2> R<3> with the corresponding penem substituted in the s positions by A-HC2-L group where A is as defined above and L is a leaving group.
    公开号:SU1586516A3
    申请号:SU864027318
    申请日:1986-04-08
    公开日:1990-08-15
    发明作者:Перроне Этторе；Альпеджиани Марко；Бедески Анджело；Царини Франко；Франчески Джованни；Делла Бруна Константино
    申请人:Фармиталиа Карло Эрба С.П.А. (Фирма)；
    IPC主号:
    专利说明:

    The invention relates to a process for the preparation of novel biologically active compounds, specifically to a process for the preparation of penem compounds or their pharmaceutically acceptable alkali metal salts, which have antibacterial activity.
    The purpose of the invention is to obtain new ones. penem antibiotics possessing

    CM
    Increased antibacterial activity {against anti-ramp and 1-gram negative bacteria with slight toxicity.
    The following examples illustrate the invention.
    Example 1. 5R, 6S-6-C (1R) -Oc-ci-ethyl -2-C4- (N-methylpyrrolidiniomethyl) -phenylJ-penem-3-carboxylate (compound I).
    . A solution of 1.6 g of (3S) -C (1J) tpetbytil dimetilcililokcietilJ- (4R-C - (bytil- difenilcililokcimvtshl) -fenilJ atsetil--thio-1- (o -trifenilfosforaniliden) alkyl piloksikarbonilmetilazetidin-2-one in 16 MP of dry distilled tetrahydropyran | furan is treated with 0.95 ml of acetic acid and 1.25 g of tetrabu- | tilammonium fluoride trihydrate ..
    After 6 hours of stirring at room temperature, the solvent was distilled off in vacuo and the precipitates were distributed to dilute aqueous jBopoM NaHCOj and ethyl acetate. I The residue from the organic layer is purified by chromatography on SiOt to obtain 1.0 g of (3S) -C () tritybutyldimethylsilylloxistil} - (4R), C4- (oxymethyl) -phenyl 3-acetylthio-1 - (of triphenylphosphoric anilidene) - allyloxy-carbonylmethyl 1- | -azetidin-2-it in the form of foam. I A solution of this material in 30 ml of toluene is boiled for 7 h with reverse cooling, then the solvent is removed: And the residue is passed through a column with iSiOi (EtOAc is cyclu: lehexane as eluent). 375 mg of allyl- (5K, 65) -6-C (III) -t-butyl dimethylsilyloxyethyl) -2-A- (hydroxymethyl) phenyl-penem-3-carboxylate are obtained, e, waxy solid. IR, l) max. (CHjCl): 1790, 1710 cm-. NMR (60 MHz, CuCl3-BV), eP: 0.08 (6H, s, SiMej); 0.88 (9H, s, SiBu-tert.); 1.28 (3N, d, J 6 Hz, 3.68 (1H, dd, J 1.5 and 6 Hz, H-6); 4.2 (1H, m,); 4.5-4, 7 (4H, m., ArCH..CH); 5.2 and 5.35 (2H, each m., СНа); 5.65 (1H, d, J 1.5 Hz, H-5); 5 , 9 (1H, m.) -; 7-7.5 (4H, m. Ar), mln. Shares
    A solution of 225 mg of the indicated intermediate product in 10 ml of ethanol-free dichloromethane, cooled to -50 ° C under argon atmosphere, is treated in succession with 0.25 ml of N-methylpyrrolidine and 0.125 ml of trifluoromethane-sulfonic anhydride.
    the mixture was allowed to warm to -20 s and after 20 min, quenched with 0.1 m of aqueous HCl. The organic layer is separated, washed with brine, dried and evaporated to give a residue, triturated in a mixture of ethyl acetate and ethyl ether, thus obtaining 150 mg of allyl- (5R, 6S) -6-C (III) -t-butyl dimethylsilylloxyethylJ -2-G4- (N-methylpyrrolidini-methyl) -phenyl J-penem-3-carboxylate as a powder; IR, V max. (CHClj film) T785, 1710 cm-.
    This material is dissolved in 9 ml of tetrahydrofuran and 0.18 ml of acetic acid and 0.3 g of tetrabutylammonium fluoride trihydrate is added. The clear solution was allowed to stand for 30 hours at room temperature, then concentrated and passed through a silica gel column. The product was then eluted with aqueous MeCN. The fractions containing the product are salted out (NaCl) and the separated aqueous phase is extracted twice with fresh MeCN. The MeCN phase and MeCN extracts are combined, dried over magnesium sulfate and evaporated to give the (, acetate) allyl salt (5R, 6S) -6- (1R) -ooxyethyl-J- 2- (N-methyl-N-pyrrolidinomethyl) phenyl-shade-3-carboxylate (90 mg); IR i) max, (film): 3400-3200, 1785, 1710 cm
    90 mg of this product are treated in 6 ml of a 1: 1 mixture of tetrahydrofuran and dichloromethane, 0.03 ml of acetic acid, 9 mg of triphenylphosphine and 9 mg of tetrakis- (triphenylphosphine) -F (0).
    After 10 minutes of stirring, the addition of HOAc, PPh and catalyst is repeated and after another 15 minutes the solvents are removed in vacuo. The residue is dissolved in demineralized water and purified by reversible phase chromatography (Lee Hroprep RP-18 Merck), eluted first with water, then with a gradient in MeCN (95: 5 to 1: 1) and finally H O-MeCN-EtOH (4: 6: 1). Combine the appropriate fractions (those on SiO, izo-PgOH () HOAc (5: 1: 1, slowly moving 4 ng but)) and, in vivo, obtain 40 mg of the desired product. IR, V max. (KBr ) 3400, 1770, 1620
    NMR (20 M1c, PGO): S 1.31 (CH, d, J 6.3 Hz, CHjCH);
    2.23, 4H, m, N (f- (2.95 (3N, s,
    H
    m)
    Sp
    H
    4.0 (1H, dd ..
    , 6 and 6.0 Hz, H-6); 4.27 (1H, Gy., And 6.3 Hz, CKj-CH); 4.51 (2H, s,); 5.80 (W, d, J 1.6 Hz H-5); 7.53 (4H, a, Ph) ppm. UV, max. (HjO): 250 and 330 nm. EXAMPLE 2 (5R, 6S) -6- (1Я) -Ok seethyl -2-4- (pyridinomethiol) -phenyl J-foam-3-carboxylate (compound 5 ). A solution of 300 mg of all-1- (5K, 6S) -6- -C (1U-tert-1-dimethylsilyloxyethyl-2-2-; 4- (hydroxyvtil) phenyl-J-penem-3-carboxylate, prepared as described in Example 1, in 16 ml of dry ethanol-free dichloromethane are treated with 1.4 ml of pyridine and 0.8 ml of trifluoromethanesulfonic anhydride under nitrogen atmosphere. After 30 minutes, add 10 ml of 0.1 M aqueous HC1, separate the organic layer, wash with additional 0.1 N HCl, dried and evaporated. Dissolve 410 mg of the residue in 20 ml of tetrahydrofuran and stir for 24 hours at room temperature at in the presence of 1 ml of acetic acid and 1.6 g of tetrabutylammonium fluoride trihydrate. After removing the solvent and purification by chromatography on silica gel (then MeCN, then MeCN-H O), 250 mg of the allyl ester of the desired compound are obtained;
    IR max. (KBG): 34 SO, 1780, 1705 cm.
    UV, / MaKc. (EtOH): 256 and 336 nm. This material is dissolved in a 1: 1 mixture of tetrahydrofuran and dichloromethane and stirred under argon in the presence of 0.25 ml of acetic acid, 25 mg of PPh e and 25 mg of tetrakis trifensh1-phosphine (Pd) (0) 3.
    An additional amount of catalyst was added at intervals of 10 minutes (4x25 mg) until, according to the data, the reaction was COMPLETELY complete (elution at TLC C / K, - Eto Ac-HOAc-H O 9: 9: 15: 5) „
    After evaporation in vacuo, the residue is dissolved in water and purified by reverse phase chromatography. Marmot with freezing the last eluted fractions gives 100 mg of the desired product. .
    ten
    25
    65166
    IR, V max. (KBG): 3400, 1770, g 1600 cm-;
     NMR (200 MHz,), G: 1.29 (3N,. – D, J 6.4 Hz, CH 3 CH); 3.94 (1H, dd, / J 1.6 and 6.0 Hz, H-6); 4.24 (1H, dk | J 6.0 and 6.4 Hz, CH3 CH); 5.74 (1H, D, J 1.6 Hz, H-5); 5.80 (2H, s, 7.43 (4H, m, Ph); 8.05 (2H,
    . .N
    DC, J 6.5 and 7.7 Hz, N / O
    H
    8; 55
    (1H,
    J 7.7 Hz
    HE;
    -f
    8.90
    (2H, d, J 6.5 Hz
    H

    H
    mn.do

    l max. (RCO): 254 and 330 them. and measure 3. (5R, 6S) -6-C (1R) -OK30
    - 25 diethyl -2- 2- (pyridinomethyl) phenyl 3- -penem-3-carboxylate (compound 14).
    A mixture of 9.45 g of potassium 2-hydroxymethylbenzoate and 5 ml of chloroacetone in 100 ml of dry dimethylformamide is stirred at room temperature for 3 hours. Ethyl acetate and brine are then added and the organic layer, after washing with water, is dried and evaporated to give 10 g of acetonyl 2-hydroxymethyl benzoate as a white powder. A solution of 1 g of this material in 20 ml of dimethylformamide is stirred for 3 hours in the presence of 2.32 ml of tert-butyldiphenylsilyl chloride and 0.86.4 g of imidazole. The reaction mixture is partitioned between ethyl acetate and aqueous HC1; the dried organic phase is evaporated and the residue is triturated with n-hexane to give 0.94 g of acetonyl-45 2- (tert-butyl diphenylsilyloxymethyl) -benzoate as a white solid.
    IR spectrum, - MaKCo (CHClj): 1740 broad, 1725 cm.
    NMR spectrum (60 MHz, CDC1.), (/: 1.15 (9H, s, S.iBu-tert.); 2.15 MH, s, CHj); 4.70 (2H, s,); 5.20 (2H, s, PhCHjO); 7.2-8.2 (14H, m. Ar) ppm.
    0.78 g of this compound is added.
    40
    50
    five
    nor, dissolved in 25 ml of acetonitrile, 26.3 ml of 0.1 N. NaOH solution. The resulting mixture is concentrated in vacuo to half its volume.
    and eGylacetate is added. The mixture is acidified with dilute HC1 with stirring, the organic layer is separated, then the two are washed with brine, dried overnight and evaporated. The solid residue is triturated with n-hexane and filtered, thus obtaining 0.54 g of 2- (tertbutyldiphenylsilyloxymethyl) benzoic Acids in the form of a white solid — JQ of this product; 130-132 C.
    This product, dissolved in 30 ml of dry ethanol-free dichloromethane, is stirred for 6 hours at room temperature in the presence of 0.5 ml of thionyl chloride. The reaction mixture is evaporated in vacuo from benzene (twice), thus obtaining 2- (tertbutyldiphenylsilyloxymethyl) -benzoyl chloride, which is immediately used as such in the next step.
    A solution of 0.7 g (38) - (1U-tert-butyl-dimethyl-1-silyloxy-ethn-1 - (“trife-. Nylphosphoranylidene) allyloxycarbonylmethyl-2-oxoazetidinyl-4-thiolate of silver” in 23 mp of dry dichloromethane is reacted with 0 , 55 g of the specified acyl chloride and 0.08 mp of pyridine for 30 minutes at room temperature.
    25
    dd, J 1.5 and 4.5 Hz, H-6); 4.3 (1H, m, CH3 CH); 4.5 (2, H, d, .2); 4.7 (2H, s, ArCHjO); 4.9 (2H, s,); 5.5 (1H, d, J 1.5 Hz, H-6); 5.7 (1H, m, CH. ,,); 7.1-7.7 (14H, m, Ar) mn. share.
    To a solution of 400 mg of this material in 20 ml of dry tetrahydrofuran, 0.7 ml of acetic acid and 500 mg of tetrabutylammonium fluoride trihydrate are added. The mixture was stirred for 5 hours, the solvent was distilled off in vacuo, and the residue was purified by flash chromatography (EtOAc-White-Clox), to obtain 250 mg of allyl- (5K, 6S) -6- (1R) -tributy-dimethylsilyloxyethyl I -2 -.- ( Oxy-methyl) -phenyl-3-carboxylate foam in the form of a white foam.
    IR spectrum, V max, (film): 3400, 1790, 1705. .
    NMR spectrum (60.MHz, CDC1,), /: 0.05 (6H, s, SiMe,); 0.9 (9H, s, SiBu- tert.); 1.25 (3N, d, CHjCH); 2.3 (1H, broad s, OH); 3.8 (1H, dd, 8 and 5 Hz, H-6); 4.3 (1H, m, CHjCH); 4.52 (2H, d, J 5Hz, SNGCH CH); 4.65 2H, s, ArCHj); 5.2 (2H, m); 5.5-5.9 (1H, m);
    After adding celite and activated-30 5.85 (TH, d, J 1.8 Hz, H-5); 7.2-carbon coal is stirred an additional 7.8 (4H, m, Ar) mp. share. After 10 min, filter through celite and add 0.1 ml of pyridine and 0.1 ml of trifluoride to a successively washed with 4% HCl, fluoromethanesulfonic anhydride to brine, and aqueous NaHCOj. After flash- chromatography to give 0.8 g of (3S) - -C (1K) tretbutildimetsh1silipoksietil - - (4) -2- (tretbutildifenilsililoksime- til) -phenyl -atsetiltno-1 (-trifenil- Fosforaniliden) alliloksikarbonilme- tilZ-azetidin- 2-she in the form of foam.
    IR spectrum,. (SNS): 1740, 1660, 1610 cm.
    This intermediate product is dissolved in dry xylene and 100 ml of this intermediate product are boiled with a total of 2 mg of dry dichloromethane under nitrogen atmosphere. After 15 minutes of stirring at -40 ° C, the reaction mixture is quenched: with 4% HC1, and brine.
    40 The organic layer is separated, washed twice with brine and evaporated, a residue remains, which is triturated with ethyl ether, and the allyl hydrochloride salt is obtained (5R,
    at 7 h in the presence of 45 b8-6-C (1K) tertbuty and a methyl silyloxy catalytic amount (20 mg) of ethyl J-2 - 2- (pyridinomethyl) -phenyl peguidrohinon Cooled reactionary
    the mixture is passed through a column with
    SiO-t, the result is 0.4 g
    allyl-5E, b8) -6-C (1K) -tbutyl dime- jg
    ts1Sl1yloxyethyl -2-C2- (tert-butyl-3-carboxylate as white crystals,
    IR spectrum, i) max. (KBG): 1795,
    phenylsilypoxymethyl) -phenylC-penem-3-carboxylate.
    IR spectrum, max, (film): 1790, 1710
    NMR spectrum (60 MHz, CDCl); (P: v 0.06 (6H, s, SiMeo); 0.8 (9H, s, SiBu-tert.) 1.1-9H; s, SiBu-tert. (1.25 OG, d, J 6 , 5 Hz, CHjCH); 3.6 (1H,
    1705 cm; NMR spectrum (200 MHz, acetone d, 45 C),: 0.11-6H, s, SiMe); 0.91 (9H, s, SiBu-tert); 1.28 (3N, d, J - 6.4 Hz, CHjCH); 4.07 (1H, m, H-6); 55 4.3-4.4 (3N, m, and CH, CH),: 5.10 and 5.18 (1 H, m,); 5.68 (1H, m, CH, CH-CH); 5.95 (1H, d, J 1.7 Hz, H-5); 6.10 (2H, m, PhCH); 7.4-7.8 (4H, m, Ph); 8.19 (2H, dd.


    dd, J 1.5 and 4.5 Hz, H-6); 4.3 (1H, m, CH3 CH); 4.5 (2, H, d, .2); 4.7 (2H, s, ArCHjO); 4.9 (2H, s,); 5.5 (1H, d, J 1.5 Hz, H-6); 5.7 (1H, m, CH. ,,); 7.1-7.7 (14H, m, Ar) mn. share.
    To a solution of 400 mg of this material in 20 ml of dry tetrahydrofuran, 0.7 ml of acetic acid and 500 mg of tetrabutylammonium fluoride trihydrate are added. The mixture was stirred for 5 hours, the solvent was distilled off in vacuo, and the residue was purified by flash chromatography (EtOAc-White-Clox), to obtain 250 mg of allyl- (5K, 6S) -6- (1R) -tributy-dimethylsilyloxyethyl I -2 -.- ( Oxy-methyl) -phenyl-3-carboxylate foam in the form of a white foam.
    IR spectrum, V max, (film): 3400, 1790, 1705. .
    NMR spectrum (60.MHz, CDC1,), /: 0.05 (6H, s, SiMe,); 0.9 (9H, s, SiBu- tert.); 1.25 (3N, d, CHjCH); 2.3 (1H, broad s, OH); 3.8 (1H, dd, 8 and 5 Hz, H-6); 4.3 (1H, m, CHjCH); 4.52 (2H, d, J 5Hz, SNGCH CH); 4.65 2H, s, ArCHj); 5.2 (2H, m); 5.5-5.9 (1H, m);
    5.85 (TH, d, J 1.8 Hz, H-5); 7.2 - 7.8 (4H, m, Ar) mn. share. 0.1 ppm of pyridine and 0.1 ml of trifluoromethanesulfonic anhydride are added to the mixture.
    5.85 (TH, d, J 1.8 Hz, H-5); 7.2 - 7.8 (4H, m, Ar) mn. share. 0.1 ppm of pyridine and 0.1 ml of trifluoromethanesulfonic anhydride are added to the mixture.
    a solution of 100 mg of the indicated intermediate product in 2 mp of dry dichloromethane under a nitrogen atmosphere. After 15 minutes of stirring at -40 ° C, the reaction mixture is quenched: with 4% HC1, and brine.
    The organic layer is separated, washed twice with brine and evaporated, a residue remains, which is triturated with ethyl ether, and the allyl hydrochloride salt is obtained (5R,
    b8-6-C (1K) -trebut imethylsilyloxyethyl-2-2- (pyridinomethyl) -phenyl-p
    German 3-carboxylate as white crystals
    IR spectrum, i) max. (KBG): 1795,
    1705 cm; NMR spectrum (200 MHz, acetone d, 45 C),: 0.11-6H, s, SiMe); 0.91 (9H, s, SiBu-tert); 1.28 (3N, d, J - 6.4 Hz, CHjCH); 4.07 (1H, m, H-6); 4.3-4.4 (ЗН, m, and СН, СН),: 5,10 and 5,18 (kazzdy 1H, m,); 5.68 (1H, m, CH, CH-CH); 5.95 (1H, d, J 1.7 Hz, H-5); 6.10 (2H, m, PhCH); 7.4-7.8 (4H, m, Ph); 8.19 (2H, dd.
    n
    J 5.7 and 7.8 Hz
    -N
    -t-, -I t, J 7.8 Hz, -H and 9.05 (2H,
     -Ru-h
    d, J 5,7, HZ, -NvO)) n. share.
    H
    15
    20
    25
    thirty
    35
    Sequential treatment of this product with tetrabutylammonium fluoride and finally HOAc (PPh) (PPh) Pd under the same conditions as indicated in Example 2 gives 25 mg of the sample of the target compound.
    Zh-spectrum, V max. (KBG): 3400, 1765, 1590 cm;
    UV spectrum, /) max. () 330 nm,
    Example 4 Using the procedure of the above examples, the following compounds were prepared in a similar way.
    (5R, 6S) -6- C (1K) -Oxyethyl -2-C4- (M- -methylpiperidinomethyl) -phenyl} -penem-3-carboxylate (compound 2).
    NMR (200 MHz, DjO,), (G: 1.31 (d, J 6.4 Hz, 3N, CHj-CH); 1.70 (m, 2H, SL1.1-4); 1.94 ( f, 4H, CH gZ.); 2.96 (s, 311®, N-CK j); 3.37 (t, 4H, CH.i-2 H CHg-6); 3.99 (dd, J 1.6 and 6.0 Hz, 1H, H :: 6), 4.26 (q, J 6.0-6.4 Hz, 1H, H ::: 8); 4.50 (s, 2H, CH, -N); 5.78 (d, J 1.6 Hz, 1H.
    Ng5); 7.52 (m, 4I, - @ -; IR, max. (KVg): 1600, G / 65 cm-1
    (5R, 6S) -6 SSh) -Oksiztsht -2-4 - {(4--carbamo-1-pyridinio) -methyl -phenyl-40-nem-3-carboxylate (compound 7); NMR (200 MHz, and, 0, 22 ° C) :: 1.30 (d, J 6.3 Hz, CH,); 3.95 (dd, J 2.6 and 6.0 Hz, 1H, H-6); 4.25 (q, J 6.0 and 6.3 Hz, 1H, K-8); 45 5.75 (d, J g2 Hz, 1H, JbS); 5.88 (s, 2H, CHi-N-); 7.46 (m, 4H, H-2, H-3,
    jH: L5, H-6); 8.35 (d, J bHgc ,,
    JW, jbS); 9.08 (d, J 6.8 Hz, 2H, H-2, H-6);
    UV () A max: 252, 330 nm.
    (5R, 6S) -6- (1K) -Oxyethyl -2- 3- - (pyridinomethyl) -phenylJ-penem-3-carboxylate (compound 22);
    NMR (200 MHz, DjO, 22 C): 1.32 (d, J 6.3 Hz, 3N,); 3.96 (dd, v 1.6 6.0 Hz, 1H, H-6); 4.26 (q, J 6.0. 6.3 Hz, 1H, H-8); 5.78 (d.
    J t, 6 Hz, 1H, H-5); 5.82 (s, 2H, 8.72 (1.H, CH.-N); 7.50 (-, 4H, 1b3, HZT-.); 8, be (dd, J 6.5, 5 6.5 Hz, 2H, HH, 1H5); 8.57 (dm, J 1.2, 6.5 Hz, 1H,); 8.91 (dd, J 1.2, 6.5 Hz, 2H, H, H :: b);
    IR (KBr), V max: 1600, 1750 cm.
    UV (H ,, 0) max: 254, 328 nm. 10 (5R, 6S) -6- (1R) -Oxyethyl (L-metsh1pyrrolidiniomethyl) -Lesht; / - pen-3-carboxylate (compound 23),
    NMR (200 MHz, DjO, 22 C): 1.33 (d, J 6.3 Hz, 3N, CH3-CH); 2.27 (m, 4H.,); 2.97 (s, 3H, ®®CHj; 3.4-3.6.6 (m, 4H, CH2-2, CH., - 5); 4.01 (dd, J 1.6, 6.0 Hz , 1H, C :: 6); 4.29 (q, J 6.0, 6.3 Hz, 1H, 1b8); 4.51 (s, 2H,); 5.82 (d, J 1.6 Hz, 1H,); 7.57 (m, 4H, H-2: Ijl4, 1b5,
    IR (KBG), l; max .: 1600, 1760 cm;
    UV () L max .: 236, 328 nm.
    II P m ime 5. (5R, 6S) -6-C (1R) -OK-seethyl J-2- (N-methylpiperidino) -acetotoxymethyl-Penem-3-carboxylate (compound 41),
    A solution of 480 mg of ally- (5R, 6S) -6- - C (1K) -t-butyldimethylsilyloxyethyl--2- (hydroxymethyl-penem-3-carboxylate in 15 ml of dry dichloromethane is successively treated with 790 mg of triphenylphosphine, 420 mg of tert.butyldiphenylsyloxyloxyxylicone acid and 0.475 ml of diethyl isothiazocarboxylate. The medium-exothermic reaction occurs and is quickly completed. The solvent is removed and the residue is purified by chromatography on silica gel, thus obtaining 700 mg of allyl- (5K, 6S) -6- (1R) -terbityl-dimethyl-ethylmethyl-1). 2- (tert-butyldiphenylsilyloxy) -acetoxymethyl - ;; -penem-3-carboxylate.
    IR spectrum, max. (CHC1): 1780, 1740, 1710
    This material is dissolved in 30 ml of a tetrahydrofuran solution of 630 mg of tetrabutylammonium fluoride trihydrate and 0.92 mg of acetic acid. After 1 hour at room temperature, the solvent is removed and the residue is purified by chromatography on silica gel, to obtain 250 mg of allyl (5R, 6S) -6-Ij (1R) -t-retbytesIdimethylsilyloxyethylJ-2- - C (hydroxymethyl) acetoxymethyl foam - 3-carboxylate as a yellowish oil;
    IR spectrum, max. (SNC.): 1785,
    50
    15
    20
    25
    thirty
    35
    - 15865
    MMl-spectrum (60 MHz, CDCli), O, (6H, c, SiMej); 0.9 (9H, s, 51Bi-tert.); : i, 25 (3N, d ,, СНзСН); 3, 70 (1H, dd, J 1 1.5 and 4.5 Hz, N); 4.2 (3N, m, ICOCHjO-CHgCH); 4.75 (2H, m, COjCH); : 5, 5.4 (2H, each, m, CH); 5.35 (2H, ABc, J 15 Hz,); 5.6 (1H, d, J 1.5 Hz, H-5); 5.8-6.2; (1H, m, CH-CH-2) ppm.
    200 mg of the specified intermediate product is dissolved in 10 ml of dry dichloromethane and the solution cooled to -70 ° C is treated in a nitrogen atmosphere successively with 0.22 ml of N-methylpyrrolidine and 0.17 ml of trifluoromethanesulfonic anhydride. After 10 minutes, the reaction mixture was diluted with more dichloro with methane, washed with 4% aqueous HC1, then with water, dried and evaporated.
    The oily residue is stirred for 20 hours in 8 ml of a tetrahydrofuran solution, 0.5 ml of acetic acid and
    : 470 mg tetrabutylammonium fluoride trihydrate

    The solvent is then removed and the residue is loaded onto a column of SiO filled with dichloromethane. Sequential elution, EtOH 1: 1, EtOH-MeCN gives some impurities, while the target salts of allyl- (5I, 6S) -6- (j (1K) -oxyethyl 3-21 - (1-methylpyrrolidinio) -acetoxime- thyl} -pene-3-carboxylate is collected
    : eluted with 35% aqueous MeCN. Collect the fractions, the content of the product, pour the NaCl and extract
    MeCN. ,
    The organic extracts are dried and evaporated, the residue is treated with 10 nl of dry dichloromethane, containing 0.2 ml of HOAc and 50 mg of triphenylphosphine, then 40 mg of tetrakis triphenylphosphine (Pd) (0) J is added.
    After 30 minutes of stirring at room temperature, the catalyst is filtered off and, after removing the solvent, the crude product is dissolved in water and purified by chromatography on a reversible phase (Lee Hroprep RP-18, Merck, water).
    The target product is eluted with HiO-MeCN and freeze dried; white powder 40 mg
    IR spectrum, 4 max. (KBG): 3400, 1765, 1610 cm.
    6
    12
    UV / max (HjO): 258 and 308 nm, NMR spectrum (200 MHz, 1) 0), tf: 1.29 (3N, d, J 6.4 Hz, CHjCH); 2.24 (4H,
    / -r
    + N (1 J Ln
    3.27 (ZN, s,
    H
    3.6-3.9 (4H, m, +

    dd, j 1.4 and 5.9 Hz, H-6); 4.24 (1H, dc, J 5.9 and 6.4 Hz, CHjCH); 4.45 (2H, s, CH, jN); 5.22 and 5.63 (2H, ABc J 14.0 Hz, 2-CH,); 5.68 (1H, d, J 1.4 Hz, H-5) mp. share.
    EXAMPLE 6. (5R, 6S) -6-r (1R) - -Oxyethyl -2-СЗ- (K-metsh1pyrrolidinio) - propyl-foam-3-carboxylate (compound 31).
    To a solution of 400 mg of allyl- (5K, 6S) -6 C (1K) tert-butyldimethylsilyloxy-methyl} -2- (3-hydroxypropyl) -penem-3-carboxylate in 15 ml of dry, not containing ethanol, dichloromethane, cooled to -30 ° C Under nitrogen atmosphere, 0.47 ml of N-methylpyrrolidine and 0.36 ml of trifluoromethane-sulfonic anhydride are added successively.
    The bath is removed and the reaction mixture is left at room temperature until most of the starting material disappears (control by those). Additional dichloromethane and 0.1 m aqueous HC1 are added with stirring and the separated organic phase is washed with brine, dried and evaporated, an oily residue is obtained, mainly consisting of 1O from salts (chloride, triflate) allyl- (5H, 6S) (1R) -TethyldimethylsilyloxyethylZ-2- 3- (N-methylpyrrolidino) propyl J-penem-3-carboxylate.
    Without purification, this material was added to a solution of 1.8 g of tetrabutylammonium fluoride trihydrate in 15 ml of tetrahydrofuran and 1 ml of acetic acid, desilylation was monitored by TLC. After the completion of the reaction, the solvent is distilled off in vacuo and the residue is purified by flash chromatography (CHCl3-MeCN and then MeCN-HO).
    0.27 g of the obtained product (allyl ester of the expected product) is stirred for 30 minutes under a nitrogen atmosphere in a mixture of 50 mg and three
    13
    Phenylphosphine and 50 mg of tetrakis triphenylphosphine palladium in (7 ml + 7 ml) of lichloromethane-tetragndrofuran and 0.5 MP acetic acid. After the removal of the solvent, the catalysts are filtered off, the solution is passed through a column with Lee Hroprep RP-18 Merck, eluted with water, and then with 10% YeSK in water.
    1586516
    14 max:
    After drying by rel-vatTTN ... with tTnG fractions, 7P mg „. By. ,, o„ ° penem formulas are obtained.
    1765, 1605 cm UV spectrum, Example 7,
    70 mg of the desired product are obtained as fractions.
    IR spectrum, max. (KBG): 3400, 1605 cm-1
    Max. (): 304 to them.
    - - -...,. (5R, 6S) -6-t (1R) -ooxy-ethyl 2- {4- (3,5-dime-methylpyridino) -methyl J-phenyl-3-carboxylate (compound 54).
    Work according to the method of example 2, but using 3,5-dimethylpyridine instead of pyridine, 700 mg of the desired product are obtained.
    UV spectrum, (II O) max: 328, 268 nm.
     NMR spectrum (200 l {ru, .DjO) S, ppm: 1.30 (3N, d, J 6.2 Hz); 2.47 (6H, s); 3.93 (1H, d, J 1.6 and
    IR (KVG), V max: 1
    1630 cm -;
    Penemous compounds in the indicated manner, in terial agents with rum action.
    Compared to each other, for example
    20
    A-CH COiZ
    or penem connections
    HE
    X-VA-CH
    25
    5.8 Hz); 4.25 (1H,
    DK, J 5.8
    6.2 Hz); 5.68 (2H, s); 5.73 (1K, d, J 1.6 Hz); 7.3-7.4 (4H, m); 8.19 (1H, m); 8.55 (2H, m). . Example 8. (5R, 6S) -6- |: (1R) - -Oxyethyx (3-carboxymethylpyridinio) methylphenylL-penem-3-carboxylate (FCE25165).
    Using the procedure of Example 2 and replacing pyridine allyl-3-carboxylate methyl pyridine, the title compound is obtained.
    UV (HjO), max 260, 331 nm.
    PRI me R 9.
     Sodium (5R, b8) -6- (1E) -Oxyethyl -2-L4- (4-carboxypyridino) -methylphenyl-penene-3-carboxylate (FCE25133A).
    Using the procedure of Example 2, replacing Pyvdin alkyl-4-carboxylate pyridine, the title compound is obtained.
    UV (NC, O), A max: 258 (short), 330 nm.
    Example 10. (5R, 6S) -6-D (R) - -Oxyethyl 2-4- (K-carboxymethyl-H- -pyrrolidino) -methylphenyl penem-3- -carboxylate (FCE 25126).
    Using the procedure of Example 1, by replacing and-methylpyrrolidine allyl with N-carboxyl-methyl-pyrrolidine, the title compound is obtained
    thirty
    35
    where Q is an amine in a partial ammonium
    they are characterized by the known activity of the ince of gram-positive, gram-negative strains
    In addition, comparatively penemous compounds are unusually prevalent in plasma and LIV and VIVO after parenteral, they exhibit a high c. In the treatment of information as Gram-positive, Gram-negative bacteria are very insignificant.
    In tab. 1 shows ak 1p vitro of a typical compound (1) of compound 5 along with 45 classical similars 21420 and the third generation of rin-Cefataxi.
    In tab. 2 shows an ac vitro of compound 5.
    In tab. 3 shows the re-testing of the antibacterial properties of various representative penemous compounds.
    50
    55 As can be seen from the table. 3, by the proposed method of a novel compound of formula (I), an improved antibacterial as compared with the known method

    sixteen
    14 max:
    with ttnG penem formul
    IR (KBG), V max: 1780, 1690.
    1630 cm -;
    The penem compounds obtained by this method are antibacterial agents with a wide spectrum of action.
    Compared to other penem compounds, for example sodium
    COiZ
    or penem compounds of formula
    HE
    X-VA-CHiQ
    25
    thirty
    35
    where Q is an amine instead of quaternary ammonium
    they are characterized by significantly inactivated in vitro activity against both gram-positive and gram-negative strains.
    In addition, compared to the known penem compounds, they have unusually long UR in plasma and in in VIVO after parenteral administration, they exhibit a high degree of efficacy. in the treatment of infections caused by both gram-positive and gram-negative bacteria, and have very little toxicity.
    In tab. Figure 1 shows the in vitro activity of a typical compound of the formula (1) of compound 5 compared with the five classic similar foams: FCE 21420 and the third generation of cephalosporin-cefataxi.
    In tab. 2 shows the in vitro activity of Compound 5.
    In tab. 3 shows the results of tests of antibacterial activity of various representatives of the new penem compounds.
    0
    55 As can be seen from the table. 3, the new penem compounds of formula (I) obtained by the proposed method show improved antibacterial activity in comparison with the known penem.
    Ri is unsubstituted or substituted by a carboxy group C | -C-alkyl, and RI and Rj, taken together with the nitrogen atom to which they are attached, form pyrrolidine Il or piperidyl, or
    K ,, rj and
    Kj taken together
    with a nitrogen atom, they form pyridinyl, unsubstituted or substituted by two C, -C-alkyls or one carbamoyl, carboxy or carboxy-C, -C-alkyl group, and their pharmaceutically acceptable alkali metals , distinguished by 4c and in that the compound of general formula (II)
    Missile defense
    COZ
    where A, PG and Z have the indicated meanings,
    with trifluoromethanesulfonic anhydride in the presence of an excess of the amine of general formula (11) in an organic solvent at a temperature of (-100) - (+ 40) C, followed by removal of the protective groups with fluoride ions in an acidic medium, or by transallylation and the target compound is ejected in free form or in the form of a pharmaceutically acceptable alkali metal salt.
    Table 1
    Proteuc, morpanii
    ATCC 25830 P. rettgerv ATCC 9250 Citrobactu friund.i.i
    ATCC 8090 Serratia marcescem
    ATCC 2902 Pseudomonas alruginosa
    2598
    0.037 0.018
    five
    OH
    J i
    OH
    21420
    Ih s
    --S-Y
    O N-kpp, Na
    CO-iNa
    Strain
    Staphilococcus aureus
    Smith
    Escherichia coli G
    Klebsiella penuraonial
    F 15724
    tagging. E / C is determined after a single intravenous dose (10 mg / kg mass); these plasma concentrations versus time are better described according to the two sections of the open model with a tabular t 1/2: intraperitoneal infection in mice; 3 x Ldg -; treatment after 30, 90 and 360 minutes after infection.
    pp Na
    CO-iNa
    Table 2
    Mg / kg dose, cumulative dose
    0.06 0.5
    0.8
    nineteen
    1586516
    20 Table 3
    权利要求:
    Claims (1)
    [1]
    Claim
    A method of obtaining penem compounds of formula (I) where R p R t , R 3 has the indicated meanings, is reacted with an intermediate penem compound of the formula
    IV
    OPG is phenylene, linear C ^ C ^ alkylene or a group-C-O (C 4 -C + ) alkylene;
    A- CH OSOjCF ^
    CO-iZ 'where A has the indicated meanings;
    q + is a group of the general formula: N—
    h
    PG - tert-butyldimethylsilyl;
    Z r is C-alkenyl obtained by reacting a carbinol of formula (III) where Rf is unsubstituted or substituted by carboxy group C | -C 4 ~ alkyl, and H g and R 3 taken together with the nitrogen atom to which they are attached form pyrrolidinyl or piperidyl, or Rj, R 2 and R 3 , taken together with a nitrogen atom, form pyridinyl unsubstituted or substituted with two C | -C ^ -alkyl-jq mi or one carbamoyl-, carboxy- or carboxy-C, -C ^ -alkyl group, or their pharmaceutically acceptable alkali metal soda, characterized in that the compound of General formula (II)
    OPC
    A-cn 2 op co 2 z 'where A, PG and Z' have the indicated meanings, with trifluoromethanesulfonic anhydride in the presence of an excess of an amine of the general formula (II) in an organic solvent at a temperature of (-100) - (+ 40) ° С followed by removal of the protecting groups with fluorine ions in an acidic medium, or transallylation, and the target compound is isolated in the free form or as a pharmaceutically acceptable alkali metal salt.
    Table 1
    Strain Connection 5 * GSE 21420 ** Cefataxime 1 • 2 3 4 Staphylococcus aureus Smith0.01.1 0,046 0.77 S. aureus 209P 0.005 0,046 1,56 S. epedermis0.19 0.76 6.25 Streptococcus faecalis (4-strains)0.06 0.1 10 S. pyogenes ATCC 12384 0.001 0,022 1.25
    Klebsiella aerogenes
    1522 E 0.38 1.55 0,095 K. alrogenes 1082 E 0.38 0.76 6.25 Escherichia coli 026: B6 0.19 0.76 0.38 E. coli 026: B6 cefR (IV) 0.38 3.12 1.25
    ) 7 1586516
    Continuation of the table. 1 - 1 | i 4 Proteus morpanii ATCC 25830 0.38 1,52 0,037 R. rettgerv ATCC 9250 0.38 1, 52 0.018 Citrobactu friundii ATCC 8090 0.19 1,52 - Serratia marcescem ATCC 2902 0.76 3.12 - Pseudomonas alrugin osa 2598 25 100 25
    * Connection 5 * FCE 21420 ^ OSOS
    C0 2 Nq
    table 2
    Strain IU 0 , mg / kg, cumulative dose Staphilococcus aureus Smith 0.06 Escherichia coli G 0.5 Klebsiella penumonial F 15724 0.8
    Note. CD 5o is determined after a single intravenous dose (10 mg / kg mouse); plasma concentration data versus time are better described according to two sections of an open model with tabular t 1/2: intraperitoneal infection in mice; 3 x LD £ - 0 ; treatment after 30, 90 and 360 minutes after infection.
    . 19 1586516 20T a b l yes 3 Connection example StaphylococcusAureusSraith StreptococcusPyogenesATCC 12384 Streptococ aus Faualis ATCC 8043 Enterobacter Coacal 1321 E. Esherichia coli IN Cef.r FCE 21420(famous fines) 0,046 0,022 12.5 1,563.12 1(FCE 24275) about 0,045 0.005 6.25 0.781,56 Ζ(FCE 24362) 0.011 0.0011 1.55 0.380.76 (compound 7)(FCE 24827) 0.01 1 $ 0.005 1,56 0.190.39 (compound 2)FCE 24957 0,045 0,022 3.12 1, 56 h(compound 22)(FCE 24492) /. 0.011 $ 0.005 3.12 0.780.78 (compound 23) - (FCE 24493) 0,045 $ 0.005 3.12 -1,56 (FCE 24372) 0,045 $ 0.005 12.5 -3.12 ABOUT(FCE 24384)7 0,045 £ 0.011 - -3.12 /(FCE 24621) 0.09 0.01 1 3.12 1, 561, 56 ABOUT(FCE 25165) 0.09 0.09 0.78 0.390.39 At(FCE 25133) 0.09 0,022 6.25 0.390.78- 10(FCE 25226) 0.09 0,022 6.25 0.390.19
    类似技术:
    公开号 | 公开日 | 专利标题
    USRE34960E|1995-05-30|Carbapenem compounds, and compositions containing them
    SU1122227A3|1984-10-30|Method of obtaining 6beta-oxyalkylpenicillanic acid derivatives or their pharmaceutically suitable basic salts
    US4181800A|1980-01-01|2-Azetidinone compounds and processes for preparation thereof
    SU1586516A3|1990-08-15|Method of producing penem compounds or their pharmaceutically acceptable salts of alkali metals
    HU206118B|1992-08-28|Process for producing beta-lactam derivatives and pharmaceutical compositions comprising same
    SE449489B|1987-05-04|BETA-LAKTAM ASSOCIATES WITH ANTIBACTERIAL AND BETA-LACTAM INHIBITIVE ACTIVITY
    BG60539B2|1995-07-28|Antibacterial preparations
    DE60014143T2|2006-03-02|ANTIMICROBIAL 4-OXOCHINOLICINE WITH 2-PYRIDONE SCUFFS AS PARTIAL STRUCTURE
    US4446146A|1984-05-01|β-Lactam containing compounds, their preparation and use
    CA2118961A1|1994-09-17|Novel 2-thiosubstituted carbapenems
    Wolfe et al.1968|Rearrangement of penicillins to anhydropenicillins
    FI82697C|1991-04-10|FRAMEWORK FOR THE FRAMEWORK OF THE PHARMACEUTICAL SYSTEM IN TAUTOMERA TIONER.
    KR880001069B1|1988-06-20|Carbapenem antibiotics and process fpr preparation thereof
    US4155912A|1979-05-22|2-Methylpenem-3-carboxylic acid antibiotics
    SU1493108A3|1989-07-07|Method of producing derivatives of 7-oxo-1-azabicyclo | hept-2-ene-2-carbolic acid
    US4347355A|1982-08-31|Inhibitors of transpeptidase
    FI89490B|1993-06-30|For example, 2-methoxymethyl penem derivatives are obtained
    CA1275405C|1990-10-23|Penem derivatives
    FR2542316A1|1984-09-14|PROCESS FOR THE PREPARATION OF CARBAPENEM DERIVATIVES, NOVEL INTERMEDIATES FOR SYNTHESIS AND PROCESS FOR THE PREPARATION OF SUCH INTERMEDIATES
    SU1195908A3|1985-11-30|Method of producing 2-oxo-1-azetidinesulfoacid derivatives or their salts with alkali metals
    CH636617A5|1983-06-15|Process for preparing cephalosporin analogues
    JP2708576B2|1998-02-04|Carbapenem derivatives
    JP2003012670A|2003-01-15|4-oxoquinolizine-based compound having antimicrobial activity
    Jung et al.1993|SYNTHESIS AND STRUCTURE-ACTIVITY RELATIONSHIPS OF NEW CEPHALOSPORINS WITH AMINOIMIDAZOLES AT C-7 EFFECT OF THE pKa OF THE C-7 AMINOIMIDAZOLE ON ANTIBACTERIAL SPECTRUM AND β-LACTAMASE STABILITY
    EP0133670A2|1985-03-06|Process for the preparation of 7-acylamino-3-hydroxy-cephem-4-carboxylic acids and 7-acylamino-3-hydroxy-1-dethia-1-oxacephem-4-carboxylic acids
    同族专利:
    公开号 | 公开日
    FI85707B|1992-02-14|
    FI861503A0|1986-04-09|
    CS258140B2|1988-07-15|
    PT82356A|1986-05-01|
    IE58856B1|1993-11-17|
    HU194892B|1988-03-28|
    EP0201206A1|1986-11-12|
    AU5590786A|1986-10-16|
    NZ215716A|1989-03-29|
    IE860918L|1986-10-10|
    JPS61236782A|1986-10-22|
    FI861503A|1986-10-11|
    ES8706690A1|1987-06-16|
    KR860008185A|1986-11-12|
    IL78427A|1990-11-29|
    KR930007415B1|1993-08-10|
    AU588301B2|1989-09-14|
    CN1021735C|1993-08-04|
    NO167291B|1991-07-15|
    SU1487813A3|1989-06-15|
    DK170341B1|1995-08-07|
    DK159586D0|1986-04-09|
    CN86102350A|1986-12-31|
    NO861368L|1986-10-13|
    AT54918T|1990-08-15|
    NO167291C|1991-10-23|
    ZA862618B|1986-12-30|
    PT82356B|1988-10-14|
    ES553742A0|1987-06-16|
    IL78427D0|1986-08-31|
    HUT40803A|1987-02-27|
    DK159586A|1986-10-11|
    CA1281713C|1991-03-19|
    DE3672886D1|1990-08-30|
    GR860925B|1986-07-29|
    FI85707C|1992-05-25|
    EP0201206B1|1990-07-25|
    JPH0735383B2|1995-04-19|
    PH22294A|1988-07-22|
    GB8509180D0|1985-05-15|
    CS253586A2|1987-11-12|
    US4863914A|1989-09-05|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    JPS5625110A|1978-12-18|1981-03-10|Bristol Myers Co|Antibacterial|
    IL58576A|1978-12-18|1985-12-31|Bristol Myers Co|2-substituted and 2,6-disubstituted penem compounds,their preparation and pharmaceutical compositions containing them|
    US4742052A|1981-07-15|1988-05-03|Sumitomo Pharmaceuticals Company, Limited|Antibacterial β-lactam compounds|
    NO831160L|1982-04-08|1983-10-10|Erba Farmitalia|PREPARATION OF SUBSTITUTED PENEM DERIVATIVES|
    PH21930A|1982-11-16|1988-04-08|Ciba Geigy Ag|6-hydroxy-lower alkylpenem compounds,pharmaceutical composition containing same and method of use thereof|
    EP0125207A1|1983-05-06|1984-11-14|Ciba-Geigy Ag|2-Tetrazolylpropyl-2-penem derivatives, process for their preparation, pharmaceutical compositions containing them and their use|
    GB8416652D0|1984-06-29|1984-08-01|Erba Farmitalia|Penem derivatives|EP0275233A1|1987-01-14|1988-07-20|Ciba-Geigy Ag|2-Heterocyclylalkyl-2-penem compounds|
    GB8416651D0|1984-06-29|1984-08-01|Erba Farmitalia|Penem derivatives|
    GB8509181D0|1985-04-10|1985-05-15|Erba Farmitalia|Penem derivatives|
    CA1339860C|1985-06-17|1998-05-12|Tsunehiko Soga|Derivatives of penem|
    EP0233155A1|1986-02-14|1987-08-19|Ciba-Geigy Ag|Aminoacyloxymethyl compounds|
    GB8605549D0|1986-03-06|1986-04-09|Erba Farmitalia|Penem derivatives|
    DE3882730D1|1987-02-11|1993-09-09|Ciba Geigy Ag|BICYCLIC BETA LACTAM CARBON ACIDS.|
    GB9113427D0|1991-06-21|1991-08-07|Erba Carlo Spa|Penem derivatives|
    TW383308B|1993-08-24|2000-03-01|Hoffmann La Roche|2-beta-alkenyl penam sulfones as beta-lactamase inhibitors|
    US6215397B1|1996-08-13|2001-04-10|Lindskog Innovation Ab|Electrical manually portable security case for the storage of theft attractive articles with an electrical mat having at least one elongated electrically conductive wire in a substantially continuous mesh, loop or eye structure|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    GB858509180A|GB8509180D0|1985-04-10|1985-04-10|Penem derivatives|
    [返回顶部]